1、ESMO临床实践指南骨髓增生异常综合征的诊断治 Annals of Oncology 17. Rigolin GM, Cuneo A, Roberti MG et al. Exposure to myelotoxic agents and myelodysplasia: case-control study and correlation with clinicobiological ndings. Br J Haematol 1998; 103: 189197. 18. Valent P, Horny HP, Bennet JM et al. Denitions and standards
2、in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007; 31: 727736. 19. Jaffe ES, Harris NL, Stein H et al. (eds. World Health Organization Classication of Tumours, Pathology and Genetics of Haematopoietic and Lymphoi
3、d Tissues. Lyon: IARC Press, 2008, pp. 75104. 20. Valent P, Horny HP. Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions. Eur J Clin Invest 2009; 39: 548553. 21. Germing U, Hildebrandt B, Pfeilstcker M et al. Renement of the interna
4、tional prognostic scoring system (IPSS by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS. Leukemia 2005; 19: 22232231. 22. Haase D, Germing U, Schanz J et al. New insights into the prognostic impact of the karyoty
5、pe in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007; 110: 43854395. 23. Mohamedali A, Gken J, Twine NA et al. Prevalence and prognostic signicance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blo
6、od 2007; 110: 33653373. 24. Boultwood J, Wainscoat JS. Gene silencing by DNA methylation in haematological malignancies. Br J Haematol 2007; 138: 311. 25. Shaffer LG, McGowan-Jordan J, Schmid M (eds. ISCN: an International System for Human Cytogenetic Nomenclature. Basel: S. Karger, 2013. 26. Haferl
7、ach C, Rieder H, Lillington DM et al. Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes. Genes Chromosomes Cancer 2007; 46: 494499. 27. Sol F, L
8、uo E, Sanzo C et al. Identication of novel cytogenetic markers with prognostic signicance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica 2005; 90: 11681178. 28. Schanz J, Steidl C, Fonatsch C et al. Coalesced multicentric analysis of 2,351 patients with myelodyspla
9、stic syndromes indicates an underestimation of poorrisk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol 2011; 29: 19631970. 29. Valcrcel D, Adem V, Sol F et al. Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in
10、patients with primary myelodysplastic syndrome. J Clin Oncol 2013; 31: 916922. 30. Schanz J, Tchler H, Sol F et al. Monosomal karyotype in MDS: explaining the poor prognosis? Leukemia 2013; 27: 19881995. 31. Yoshida K, Sanada M, Shiraishi Y et al. Frequent pathway mutations of splicing machinery in
11、myelodysplasia. Nature 2011; 478: 6469. 32. Papaemmanuil E, Gerstung M, Malcovati L et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013; 122: 36163627. 33. Westers TM, Ireland R, Kern W et al. Standardization of ow cytometry in myelodysplastic syn
12、dromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia 2012; 26: 1730 1741. 34. Swerdlow SH, Campo E, Harris NL et al. (eds. WHO Classication of Tumours of Haematopoietic and Lymphoid Tissues, 4th edition. Lyon: IARC Press, 2008. 35. Tefferi A, Vardima
13、n JW. Myelodysplastic syndromes. N Engl J Med 2009; 361: 18721885. 36. Sanz GF, Sanz MA, Vallespi T et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989
14、; 74: 395408. 37. Voso MT, Fenu S, Latagliata R et al. Revised International Prognostic Scoring System (IPSS predicts survival and leukemic evolution of myelodysplastic syndromes signicantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Re
15、gional Database. J Clin Oncol 2013; 31: 26712677. clinical practice guidelines 38. Malcovati L, Hellstrm-Lindberg E, Bowen D et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 2013; 122: 29432964. 39. Della Porta MG, Ma
16、lcovati L, Boveri E et al. Clinical relevance of bone marrow brosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol 2009; 27: 754762. 40. Malcovati L, Germing U, Kuendgen A et al. Time-dependent prognostic scoring system for predicting survival and leukemic evoluti
17、on in myelodysplastic syndromes. J Clin Oncol 2007; 25: 35033510. 41. Estey EH, Thall PF, Cortes JE et al. Comparison of idarubicin + ara-C-, udarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anaemia with excess blasts in tran
18、sformation, or refractory anaemia with excess blasts. Blood 2001; 98: 35753583. 42. Fenaux P, Mufti GJ, Hellstrm-Lindberg E et al. Efcacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III stu
19、dy. Lancet Oncol 2009; 10: 223232. 43. Gurion R, Vidal L, Gafter-Gvili A et al. 5-azacitidine prolongs overall survival in patients with myelodysplastic syndromea systematic review and meta-analysis. Haematologica 2010; 95: 303310. 44. Gore SD, Fenaux P, Santini V et al. A multivariate analysis of t
20、he relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica 2013; 98: 10671072. 45. Knipp S, Hildebrand B, Kndgen A et al. Intensive chemotherapy is not
21、 recommended for patients aged 60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. Cancer 2007; 110: 345352. 46. Kantarijan HM, OBrien S, Huang X et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodys
22、plastic syndrome: comparison with historical experience. Cancer 2007; 109: 11331137. 47. Zwierzinq H, Suciu S, Loefer-Ragg J et al. Low-dose cytosine arabinoside (LD-AraC vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patie
23、nts with a high risk of developing acute leukemia: nal results of a randomized phase III study (06903 of the EORTC Leukemia Cooperative Group. Leukemia 2005; 19: 19291933. 48. Cheson BD, Simon R. Low-dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a review of 20 years expe
24、rience. Semin Oncol 1987; 14(2 Suppl 1:126133. 49. Fenaux P, Lai JL, Gardin C et al. Cytogenetics are a predictive factor of response to low dose Ara-C in acute myelogenous leukemia (AML in the elderly. Leukemia 1990; 4: 312. 50. Prebet T, Gore SD, Esterni B et al. Outcome of high-risk myelodysplast
25、ic syndrome after azacitidine treatment failure. J Clin Oncol 2011; 29: 33223327. 51. Brand R, Putter H, van Biezen A et al. Comparison of allogeneic stem cell transplantation and non-transplant approaches in elderly patients with advanced myelodysplastic syndrome: optimal statistical approaches and
26、 a critical appraisal of clinical results using non-randomized data. PLoS One 2013; 8: e74368. 52. Vaughn JE, Scott BL, Deeg HJ. Transplantation for myelodysplastic syndromes 2013. Curr Opin Hematol 2013; 20: 494500. 53. Guardiola P, Runde V, Bacigalupo A et al. Retrospective comparison of bone marr
27、ow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood 2002; 99: 43704378. 54. Mittelman M, Oster HS, Hoffman M, Neumann D. The lower risk MDS patient at
28、risk of rapid progression. Leuk Res 2010; 34: 15511555. 55. Bejar R, Stevenson KE, Caughey BA et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2012; 30: 33763382. 56. Kelaidi C, Park S, Sapena R et al. Long-term o
29、utcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents. Leukemia 2013; 27: 12831290. 57. Fenaux P, Rose C. Impact of iron overload in myelodysplastic syndromes. Blood Rev 2009; 23 (Suppl 1: S15S19. Downloaded from
30、http:/annonc.oxfordjournals.org/ by guest on September 16, 2014 Volume 25 | Supplement 3 | September 2014 doi:10.1093/annonc/mdu180 | iii clinical practice guidelines 58. Crawford J, Cella D, Cleeland CS et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy
31、in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002; 95: 888895. 59. Roy NB, Myerson S, Schuh AH et al. Cardiac iron overload in transfusiondependent patients with myelodysplastic syndromes. Br J Haematol 2011; 154: 521524. 60. Park S, Grabar S, Kelaidi C et al. Predictive factors
32、of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008; 111: 574582. 61. Jadersten M, Malcovati L, Dybedal I et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008; 26: 36073613. 62. Greenberg PL, Sun Z, Miller KB et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colonystimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperati
